Next‐generation ALK inhibitor vs crizotinib
Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor probably leads to higher overall response rate compared with crizotinib (moderate certainty).
1 finding from 1 review
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes onlyRR 1.18 [1.1, 1.25]5 studies · 1229 participantsModerate